MCID: CRN036
MIFTS: 65

Craniopharyngioma

Categories: Cancer diseases, Endocrine diseases, Eye diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Craniopharyngioma

MalaCards integrated aliases for Craniopharyngioma:

Name: Craniopharyngioma 12 52 58 54 6 43 15 17 71
Dysodontogenic Epithelial Tumor 52
Craniopharyngeal Duct Tumor 52
Neoplasm of Rathke's Pouch 12
Adamantinomatous Tumor 52
Rathke's Pouch Tumor 52

Characteristics:

Orphanet epidemiological data:

58
craniopharyngioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Sweden); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare endocrine diseases


Summaries for Craniopharyngioma

NIH Rare Diseases : 52 Craniopharyngioma is a slow-growing, non-cancerous brain tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain which produces several important hormones ) and the hypothalamus (an endocrine organ which controls the release of hormones by the pituitary gland). This tumor most commonly affects children between 5 and 10 years of age; however, adults can sometimes be affected. Although craniopharyngiomas are not cancerous, they may grow and press on nearby parts of the brain, causing symptoms including hormonal changes, vision changes, slow growth, headaches, nausea and vomiting, loss of balance, hearing loss , and changes in mood or behavior. The cause of these tumors is not well understood; however, researchers suspect that they begin to form during the early stages of embryo development in pregnancy (embryogenesis) and may result from metaplasia (abnormal transformation of cells ). Treatment for craniopharyngioma varies and may involve surgery to remove the tumor, radiation therapy , chemotherapy , biologic therapy , and/or hormone therapy to replace various hormones no longer produced or secreted due to the tumor or its treatment.

MalaCards based summary : Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to papillary craniopharyngioma and adamantinous craniopharyngioma, and has symptoms including visual disturbance An important gene associated with Craniopharyngioma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and hypothalamus, and related phenotypes are abnormal hypothalamus morphology and cerebral calcification

Wikipedia : 74 A craniopharyngioma is a rare type of brain tumor derived from pituitary gland embryonic tissue that... more...

Related Diseases for Craniopharyngioma

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 566)
# Related Disease Score Top Affiliating Genes
1 papillary craniopharyngioma 34.8 KRT7 CTNNB1 BRAF
2 adamantinous craniopharyngioma 33.9 PROP1 POU1F1 CTNNB1
3 hypothalamic obesity 31.8 LEPR INS IGF1
4 ameloblastoma 31.3 PTCH1 KRT8 KRT14 CTNNB1
5 diabetes insipidus 31.2 PRL INS GH1
6 teratoma 30.8 KRT7 INS CTNNB1 CDH1
7 galactorrhea 30.8 PRL IGF1
8 leptin deficiency or dysfunction 30.7 TRH LEPR INS IGF1 GNRH1 GHRL
9 papilloma 30.6 KRT8 KRT7 KRT14 CDH1
10 adenocarcinoma 30.6 KRT7 CTNNB1 CDH1 BRAF APC
11 meningioma, familial 30.5 PTCH1 PRL NF1 IGF1 CTNNB1 CDH1
12 germinoma 30.4 PTCH1 PRL CDH1
13 sleep apnea 30.4 LEPR INS IGF1 GHRL
14 non-alcoholic steatohepatitis 30.4 LEPR INS IGF1 GHRL
15 apnea, obstructive sleep 30.3 INS IGF1 GHRL
16 neuroblastoma 30.3 PTCH1 NF1 INS IGF1 CTNNB1 CDH1
17 skin carcinoma 30.3 PTCH1 KRT8 KRT7 CTNNB1 CDH1
18 amenorrhea 30.3 TRH PRL INS IGF1 GNRH1 GHRL
19 colorectal adenoma 30.2 INS IGF1 CTNNB1 CDH1 APC
20 sleep disorder 30.2 PRL INS IGF1 GHRL
21 squamous cell carcinoma 30.2 PTCH1 KRT7 KRT14 CTNNB1 CDH1 BRAF
22 hyperinsulinism 30.2 LEPR INS IGF1 GNRH1 GHRL GH1
23 impotence 30.1 PRL INS GNRH1
24 thyroiditis 30.0 TRH PRL INS BRAF
25 sexual disorder 30.0 PRL INS IGF1 GNRH1
26 pituitary adenoma 30.0 TRH PRL POU1F1 IGF1 GNRH1 GHRL
27 chromophobe adenoma 29.9 TRH PRL GH1
28 adenoma 29.9 TRH PRL POU1F1 KRT7 IGF1 GH1
29 alopecia 29.8 PRL KRT14 IGF1 CTNNB1
30 hypoglycemia 29.8 PRL INS IGF1 GHRL GH1
31 hyperprolactinemia 29.8 TRH PRL INS IGF1 GNRH1 GH1
32 insulin-like growth factor i 29.7 PRL INS IGF1 GH1
33 pituitary hormone deficiency, combined, 2 29.7 TRH PROP1 PRL POU1F1 IGF1 GH1
34 pituitary tumors 29.6 PROP1 PRL IGF1 GH1
35 isolated growth hormone deficiency 29.6 PROP1 POU1F1 IGF1 GH1
36 hypogonadism 29.5 PROP1 PRL LEPR INS IGF1 GNRH1
37 functioning pituitary adenoma 29.5 TRH PRL IGF1 GH1
38 pituitary apoplexy 29.5 TRH PRL INS IGF1 GNRH1 GH1
39 pituitary adenoma, prolactin-secreting 29.5 TRH PRL POU1F1 IGF1 GNRH1 GH1
40 body mass index quantitative trait locus 11 29.5 TRH PRL LEPR INS IGF1 GHRL
41 hypopituitarism 29.3 TRH PROP1 PRL POU1F1 INS IGF1
42 hypogonadotropic hypogonadism 29.3 PROP1 PRL LEPR INS GNRH1
43 hypothalamic disease 29.2 TRH PRL INS GNRH1 GH1
44 anorexia nervosa 29.2 PRL LEPR INS IGF1 GHRL GH1
45 turner syndrome 29.1 PRL NF1 INS IGF1 GH1
46 hyperthyroidism 29.1 TRH PRL INS IGF1 GHRL GH1
47 conn's syndrome 29.1 TRH PRL IGF1 GNRH1 GHRL GH1
48 acth deficiency, isolated 29.1 TRH PROP1 PRL
49 hypothyroidism, congenital, nongoitrous, 4 28.9 PROP1 PRL POU1F1 GH1
50 acromegaly 28.9 TRH PRL LEPR INS IGF1 GNRH1

Graphical network of the top 20 diseases related to Craniopharyngioma:



Diseases related to Craniopharyngioma

Symptoms & Phenotypes for Craniopharyngioma

Human phenotypes related to Craniopharyngioma:

58 31 (show all 48)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal hypothalamus morphology 58 31 obligate (100%) Obligate (100%) HP:0012286
2 cerebral calcification 58 31 hallmark (90%) Very frequent (99-80%) HP:0002514
3 enlarged pituitary gland 58 31 hallmark (90%) Very frequent (99-80%) HP:0012505
4 intracranial cystic lesion 58 31 hallmark (90%) Very frequent (99-80%) HP:0010576
5 neoplasm of the anterior pituitary 58 31 hallmark (90%) Very frequent (99-80%) HP:0011750
6 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
7 obesity 58 31 frequent (33%) Frequent (79-30%) HP:0001513
8 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
9 excessive daytime somnolence 58 31 frequent (33%) Frequent (79-30%) HP:0001262
10 pituitary hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0008245
11 central diabetes insipidus 58 31 frequent (33%) Frequent (79-30%) HP:0000863
12 papilledema 58 31 frequent (33%) Frequent (79-30%) HP:0001085
13 central adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011734
14 bitemporal hemianopia 58 31 frequent (33%) Frequent (79-30%) HP:0030521
15 increased circulating prolactin concentration 58 31 frequent (33%) Frequent (79-30%) HP:0000870
16 progressive visual field defects 58 31 frequent (33%) Frequent (79-30%) HP:0007987
17 abnormal visual field test 58 31 frequent (33%) Frequent (79-30%) HP:0030588
18 slow decrease in visual acuity 58 31 frequent (33%) Frequent (79-30%) HP:0007924
19 hypogonadotropic hypogonadism 31 frequent (33%) HP:0000044
20 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
21 type ii diabetes mellitus 58 31 occasional (7.5%) Occasional (29-5%) HP:0005978
22 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
23 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
24 optic atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000648
25 delayed puberty 58 31 occasional (7.5%) Occasional (29-5%) HP:0000823
26 cerebral ischemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002637
27 sleep apnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0010535
28 increased susceptibility to fractures 58 31 occasional (7.5%) Occasional (29-5%) HP:0002659
29 polyphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002591
30 proportionate short stature 58 31 occasional (7.5%) Occasional (29-5%) HP:0003508
31 intellectual disability 58 31 very rare (1%) Very rare (<4-1%) HP:0001249
32 global developmental delay 58 31 very rare (1%) Very rare (<4-1%) HP:0001263
33 myocardial infarction 58 31 very rare (1%) Very rare (<4-1%) HP:0001658
34 postnatal growth retardation 58 31 very rare (1%) Very rare (<4-1%) HP:0008897
35 vertigo 58 31 very rare (1%) Very rare (<4-1%) HP:0002321
36 recurrent infections 58 31 very rare (1%) Very rare (<4-1%) HP:0002719
37 coma 58 31 very rare (1%) Very rare (<4-1%) HP:0001259
38 sudden loss of visual acuity 58 31 very rare (1%) Very rare (<4-1%) HP:0001117
39 abnormality of the nasal bone 58 31 very rare (1%) Very rare (<4-1%) HP:0010939
40 abnormality of the frontal bone 58 31 very rare (1%) Very rare (<4-1%) HP:0430000
41 seizure 31 very rare (1%) HP:0001250
42 behavioral abnormality 58 Very rare (<4-1%)
43 seizures 58 Very rare (<4-1%)
44 sleep disturbance 58 Frequent (79-30%)
45 growth delay 58 Occasional (29-5%)
46 hypogonadism 58 Frequent (79-30%)
47 low gonadotropins (secondary hypogonadism) 58 Frequent (79-30%)
48 hypopituitarism 58 Very frequent (99-80%)

UMLS symptoms related to Craniopharyngioma:


visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.02 NF1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.02 NF1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.02 GH1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.02 POU1F1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.02 KRT8
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.02 GH1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.02 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.02 GH1 KRT7 KRT8 POU1F1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.02 GH1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.02 POU1F1 NF1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.02 GH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.02 KRT8
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.02 POU1F1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.02 KRT7 KRT8 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.02 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.02 NF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.02 GH1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.02 POU1F1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-40 10.02 KRT8
20 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.02 NF1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.02 CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.02 GH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.02 GH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.02 KRT7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-72 10.02 KRT7
26 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.02 KRT7 KRT8 NF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.02 POU1F1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.02 KRT7
29 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.02 GH1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.02 POU1F1
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.56 APC
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.56 APC
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.56 APC
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-6 9.56 KRT8
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.56 KRT7 KRT8
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.56 APC
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 9.56 APC

MGI Mouse Phenotypes related to Craniopharyngioma:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 APC BRAF CDH1 CTNNB1 GHRL GNRH1
2 endocrine/exocrine gland MP:0005379 10.49 APC BRAF CDH1 CTNNB1 GHRL GNRH1
3 growth/size/body region MP:0005378 10.48 APC BRAF CDH1 CTNNB1 GNRH1 IGF1
4 cellular MP:0005384 10.42 APC BRAF CDH1 CTNNB1 IGF1 INS
5 digestive/alimentary MP:0005381 10.41 APC BRAF CDH1 CTNNB1 GHRL GNRH1
6 immune system MP:0005387 10.38 APC BRAF CDH1 CTNNB1 GNRH1 IGF1
7 hematopoietic system MP:0005397 10.37 APC BRAF CTNNB1 GNRH1 IGF1 INS
8 cardiovascular system MP:0005385 10.36 APC BRAF CDH1 CTNNB1 IGF1 INS
9 mortality/aging MP:0010768 10.32 APC BRAF CDH1 CTNNB1 IGF1 INS
10 integument MP:0010771 10.3 APC BRAF CDH1 CTNNB1 GNRH1 IGF1
11 embryo MP:0005380 10.24 APC BRAF CDH1 CTNNB1 INS KRT8
12 hearing/vestibular/ear MP:0005377 10.22 APC BRAF CTNNB1 IGF1 KRT14 KRT8
13 nervous system MP:0003631 10.22 APC BRAF CTNNB1 GNRH1 IGF1 INS
14 neoplasm MP:0002006 10.21 APC BRAF CDH1 CTNNB1 GNRH1 IGF1
15 adipose tissue MP:0005375 10.17 APC BRAF GHRL IGF1 INS KRT14
16 craniofacial MP:0005382 10.15 APC BRAF CTNNB1 KRT14 NF1 POU1F1
17 liver/biliary system MP:0005370 10.15 APC BRAF CTNNB1 GNRH1 INS KRT8
18 normal MP:0002873 10.11 APC BRAF CDH1 CTNNB1 GHRL GNRH1
19 muscle MP:0005369 10.06 APC BRAF CTNNB1 IGF1 INS LEPR
20 limbs/digits/tail MP:0005371 10.05 APC BRAF CTNNB1 IGF1 LEPR NF1
21 reproductive system MP:0005389 10.03 APC BRAF CDH1 CTNNB1 GNRH1 IGF1
22 renal/urinary system MP:0005367 10 APC BRAF CTNNB1 GNRH1 IGF1 INS
23 pigmentation MP:0001186 9.87 APC BRAF CTNNB1 KRT14 NF1 POU1F1
24 respiratory system MP:0005388 9.56 BRAF CTNNB1 IGF1 KRT14 LEPR NF1
25 skeleton MP:0005390 9.36 APC BRAF CTNNB1 GNRH1 IGF1 INS

Drugs & Therapeutics for Craniopharyngioma

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4 Hydrocortisone 17-butyrate 21-propionate Phase 4
5 Hydrocortisone hemisuccinate Phase 4
6
Diazoxide Approved Phase 3 364-98-7 3019
7
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
8
Glucagon Approved Phase 3 16941-32-5
9
Donepezil Approved Phase 3 120014-06-4 3152
10
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Antihypertensive Agents Phase 3
16 Hypoglycemic Agents Phase 3
17 Vasodilator Agents Phase 3
18 Anti-Obesity Agents Phase 3
19 Incretins Phase 3
20 Glucagon-Like Peptide 1 Phase 3
21 Anesthetics Phase 3
22 Cholinesterase Inhibitors Phase 3
23 Cholinergic Agents Phase 3
24 Emetics Phase 3
25 Liver Extracts Phase 3
26 Cola Phase 3
27 Narcotics Phase 3
28 Analgesics Phase 3
29 Analgesics, Opioid Phase 3
30 Anesthetics, General Phase 3
31 Anesthetics, Intravenous Phase 3
32
Metformin Approved Phase 2 657-24-9 14219 4091
33
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
36
Histamine Approved, Investigational Phase 2 51-45-6 774
37
Cyproheptadine Approved Phase 2 129-03-3 2913
38
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
39
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
40
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
41
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
42
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
43
Memantine Approved, Investigational Phase 2 19982-08-2 4054
44
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
45
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
46
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
47
Trioxsalen Approved Phase 2 3902-71-4 5585
48
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
49
Methylphenidate Approved, Investigational Phase 2 113-45-1 4158
50
Modafinil Approved, Investigational Phase 2 68693-11-8 4236

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
3 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
4 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
5 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours Unknown status NCT03216148 Phase 2
9 Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study Completed NCT00892073 Phase 2 Diazoxide;Metformin
10 Effects of Exenatide on Hypothalamic Obesity Completed NCT01061775 Phase 1, Phase 2 Exenatide
11 Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity Completed NCT01484873 Phase 2 Exenatide
12 Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
13 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
14 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
15 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
16 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
17 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
18 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
19 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
20 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
21 A Phase I/II Study of Reirradiation for Recurrent Pediatric Brain and Spinal Cord Tumors and Primary Glioblastoma Multiforme Using the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
22 Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
23 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
24 Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
25 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
26 Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy Active, not recruiting NCT02842723 Phase 2
27 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
28 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Active, not recruiting NCT00187226 Phase 2
29 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Active, not recruiting NCT03194906 Phase 2 Memantine
30 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
31 Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma Terminated NCT01964300 Phase 2
32 A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy Terminated NCT01348607 Phase 2 methylphenidate hydrochloride;modafinil;placebo
33 A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults Terminated NCT01966809 Phase 2 Photofrin photodynamic therapy.
34 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
35 Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
36 Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms Completed NCT00019578 Phase 1
37 A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS Completed NCT00363272 Phase 1 ispinesib
38 Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
39 A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS Completed NCT00053963 Phase 1 romidepsin
40 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas Completed NCT00994500 Phase 1 vorinostat;bortezomib
41 A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
42 A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
43 Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors Completed NCT00098761 Phase 1 laromustine
44 A Trial of 06-BG and BCNU in Children With CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
45 Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
46 Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors Completed NCT00063973 Phase 1 cilengitide
47 High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies Completed NCT00053118 Phase 1 carboplatin;etoposide
48 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
49 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
50 A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors Completed NCT00544284 Phase 1 bortezomib;temozolomide

Search NIH Clinical Center for Craniopharyngioma

Cochrane evidence based reviews: craniopharyngioma

Genetic Tests for Craniopharyngioma

Anatomical Context for Craniopharyngioma

MalaCards organs/tissues related to Craniopharyngioma:

40
Brain, Pituitary, Hypothalamus, Bone, Testes, Liver, Spinal Cord

Publications for Craniopharyngioma

Articles related to Craniopharyngioma:

(show top 50) (show all 3219)
# Title Authors PMID Year
1
Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. 61 52
29220529 2018
2
First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. 52 61
28213803 2017
3
Oxytocin in survivors of childhood-onset craniopharyngioma. 61 52
27585663 2016
4
Specific behaviour, mood and personality traits may contribute to obesity in patients with craniopharyngioma. 61 52
24923438 2015
5
Novel immunohistochemical markers in the diagnosis of nonglial tumors of nervous system. 61 54
20179436 2010
6
The differential diagnosis of central nervous system tumors: a critical examination of some recent immunohistochemical applications. 61 54
18318590 2008
7
Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor. 61 54
17410335 2007
8
Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. 54 61
17556861 2007
9
[Expression of minichromosome maintenance protein 6 in craniopharyngioma and its correlation with prognosis]. 54 61
17294730 2007
10
Mutation in exon 7 of PTCH deregulates SHH/PTCH/SMO signaling: possible linkage to WNT. 54 61
16596257 2006
11
Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma. 54 61
16084764 2005
12
Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. 54 61
16000560 2005
13
Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. 61 54
15980970 2005
14
Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. 54 61
15891929 2005
15
The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. 54 61
15817911 2005
16
Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma. 61 54
15221941 2004
17
Beta-catenin mutations are frequent in calcifying odontogenic cysts, but rare in ameloblastomas. 54 61
14578169 2003
18
Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. 54 61
12466115 2002
19
Growth without growth hormone. 54 61
12510977 2002
20
Differential expression of cytokeratins 8 and 20 distinguishes craniopharyngioma from rathke cleft cyst. 54 61
12296753 2002
21
Craniopharyngioma: a case report and comparative galectin histochemical analysis. 54 61
12495217 2002
22
Pseudotumor of the pituitary due to PROP-1 deletion. 54 61
11822586 2002
23
A study of the growth-promoting and metabolic effects of growth hormone (GH) in a patient with the "growth without GH" syndrome. 61 54
11735238 2001
24
Different keratin profiles in craniopharyngioma subtypes and ameloblastomas. 54 61
11770017 2001
25
The use of insulin-like growth factor 1 reference values for the diagnosis of growth hormone deficiency in prepubertal children. 61 54
10848878 2000
26
A boy with normal growth in spite of growth hormone deficiency after resection of a suprasellar teratoma. 54 61
10890195 2000
27
Somatostatin receptor tumor imaging (Tc 99m P829) in pituitary adenoma. 54 61
10659562 1999
28
Serum IGF-I and IGFBP-3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours. 54 61
10469014 1999
29
The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood [see comment]. 61 54
8729528 1996
30
Effective use of magnetic resonance imaging in the assessment of children with possible growth hormone deficiency. 54 61
15251557 1996
31
Could craniopharyngiomas produce pituitary hormones? 54 61
8098858 1993
32
Discontinuation of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance. 61 54
8314202 1993
33
Pulsatile prolactin secretion in hyperprolactinemia due to presumed pituitary stalk interruption. 61 54
1955511 1991
34
Demonstration of insulin-like growth factors I, II and heterogeneous insulin-like growth factor binding proteins in the cyst fluid of patients with craniopharyngioma. 54 61
1719442 1991
35
Endoscopic Endonasal Surgery for Resection of Giant Craniopharyngioma in a Toddler-Multimodal Presurgical Planning, Surgical Technique, and Management of Complications: 2-Dimensional Operative Video. 61
31814025 2020
36
A rare case of giant cystic adamantinomatous craniopharyngioma in an adult. 61
32382364 2020
37
Dosimetric and volumetric outcomes of combining cyst puncture through an Ommaya reservoir with index-optimized hypofractionated stereotactic radiotherapy in the treatment of craniopharyngioma. 61
32490217 2020
38
Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population. 61
32034518 2020
39
Surgical Nuances of Endoscopic Endonasal Resection of Craniopharyngiomas: 2-Dimensional Operative Video. 61
31828350 2020
40
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. 61
32383818 2020
41
Complete Microsurgical Resection of Large Retrochiasmatic Hypothalamic Craniopharyngioma by Transpetrosal Approach: 2-Dimensional Operative Video. 61
31538198 2020
42
Pituitary surgery's epidemiology using a national inpatient database in Japan. 61
32125502 2020
43
Neurocysticercosis Presenting as an Isolated Suprasellar Lesion: Case Report. 61
32522639 2020
44
Pre- and postoperative need for pituitary hormone replacement in non-adenomatous sellar and parasellar lesions: importance of the sellar encroachment score. 61
32506330 2020
45
Excision of a Retrochiasmatic Craniopharyngioma by Transcallosal, Interforniceal Approach With Exoscope Assistance: 2-Dimensional Operative Video. 61
32497205 2020
46
Mirror meningiomas: a late rare finding after radiotherapy for childhood for a craniopharyngioma. 61
32052361 2020
47
Bariatric Surgery for Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy: a Matched Case-Control Study. 61
31955372 2020
48
Heterogeneity of Growth Hormone Receptor Expression in Craniopharyngioma-Implications for Surgical Strategy. 61
32059964 2020
49
Correction: Autonomic Dysfunction is Associated with Increased Cardiometabolic Risk in Patients with Childhood-Onset Craniopharyngioma. 61
32544969 2020
50
Autonomic Dysfunction is Associated with Increased Cardiometabolic Risk in Patients with Childhood-Onset Craniopharyngioma. 61
32512610 2020

Variations for Craniopharyngioma

ClinVar genetic disease variations for Craniopharyngioma:

6 (show all 23) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.3183_3187del (p.Lys1061_Gln1062insTer)deletion Pathogenic 88913 rs587779352 5:112174471-112174475 5:112838774-112838778
2 CTNNB1 NM_001904.4(CTNNB1):c.94G>T (p.Asp32Tyr)SNV Pathogenic/Likely pathogenic 17581 rs28931588 3:41266097-41266097 3:41224606-41224606
3 CTNNB1 NM_001904.4(CTNNB1):c.100G>A (p.Gly34Arg)SNV Likely pathogenic 376232 rs121913399 3:41266103-41266103 3:41224612-41224612
4 CTNNB1 NM_001904.4(CTNNB1):c.100G>C (p.Gly34Arg)SNV Likely pathogenic 376233 rs121913399 3:41266103-41266103 3:41224612-41224612
5 ERCC2 NM_000400.3(ERCC2):c.1361_1363TCA[2] (p.Ile456del)short repeat Likely pathogenic 620626 19:45860740-45860742 19:45357482-45357484
6 SMARCA4 NM_001128849.2(SMARCA4):c.442G>A (p.Gly148Arg)SNV Conflicting interpretations of pathogenicity 220638 rs138689221 19:11096951-11096951 19:10986275-10986275
7 SUFU NM_016169.3(SUFU):c.839G>A (p.Arg280Gln)SNV Conflicting interpretations of pathogenicity 241089 rs145704867 10:104356979-104356979 10:102597222-102597222
8 CTNNB1 NM_001904.4(CTNNB1):c.101G>T (p.Gly34Val)SNV Conflicting interpretations of pathogenicity 17582 rs28931589 3:41266104-41266104 3:41224613-41224613
9 NF1 NM_000267.3(NF1):c.4773G>A (p.Arg1591=)SNV Conflicting interpretations of pathogenicity 457720 rs1555533268 17:29652838-29652838 17:31325820-31325820
10 TSC2 NM_000548.5(TSC2):c.3846_3855delinsG (p.Ser1282_Gly1285delinsArg)indel Conflicting interpretations of pathogenicity 135377 rs587778732 16:2132468-2132477 16:2082467-2082476
11 TSC1 NM_000368.4(TSC1):c.1355G>C (p.Gly452Ala)SNV Conflicting interpretations of pathogenicity 411263 rs371093730 9:135782201-135782201 9:132906814-132906814
12 TSC1 NM_000368.4(TSC1):c.1231C>A (p.Leu411Ile)SNV Conflicting interpretations of pathogenicity 64790 rs397514840 9:135785990-135785990 9:132910603-132910603
13 TSC2 NM_000548.5(TSC2):c.3038A>G (p.Asp1013Gly)SNV Uncertain significance 406089 rs1060500961 16:2129104-2129104 16:2079103-2079103
14 BMPR1A NM_004329.2(BMPR1A):c.499A>T (p.Met167Leu)SNV Uncertain significance 187206 rs200951235 10:88659852-88659852 10:86900095-86900095
15 MSH6 NM_000179.2(MSH6):c.1657A>C (p.Thr553Pro)SNV Uncertain significance 620605 rs1294509946 2:48026779-48026779 2:47799640-47799640
16 PHOX2B NM_003924.3(PHOX2B):c.556G>A (p.Glu186Lys)SNV Uncertain significance 620600 rs1560465720 4:41748213-41748213 4:41746196-41746196
17 PTCH1 NM_000264.5(PTCH1):c.203G>A (p.Gly68Glu)SNV Uncertain significance 620601 rs757430199 9:98268880-98268880 9:95506598-95506598
18 KRAS NM_033360.4(KRAS):c.*101_*106deldeletion Uncertain significance 620625 rs1339924833 12:25362744-25362749 12:25209810-25209815
19 BRCA1 NM_007294.4(BRCA1):c.5123C>T (p.Ala1708Val)SNV Uncertain significance 37640 rs28897696 17:41215920-41215920 17:43063903-43063903
20 CDH1 NM_004360.5(CDH1):c.1225T>C (p.Trp409Arg)SNV Likely benign 133855 rs587778176 16:68847303-68847303 16:68813400-68813400
21 PTCH1 NM_000264.5(PTCH1):c.113G>A (p.Gly38Glu)SNV Benign/Likely benign 216367 rs143494325 9:98270531-98270531 9:95508249-95508249
22 TSC2 NM_000548.5(TSC2):c.3803G>A (p.Arg1268His)SNV Benign/Likely benign 65034 rs200577441 16:2131788-2131788 16:2081787-2081787
23 PTPN11 NM_002834.5(PTPN11):c.925A>G (p.Ile309Val)SNV Benign 40536 rs201787206 12:112915526-112915526 12:112477722-112477722

Cosmic variations for Craniopharyngioma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM111893549 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.79G>A p.G27R 3:41224612-41224612 8

Expression for Craniopharyngioma

Search GEO for disease gene expression data for Craniopharyngioma.

Pathways for Craniopharyngioma

Pathways related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 PTCH1 NF1 IGF1 GNRH1 GH1 CTNNB1
2
Show member pathways
13.14 IGF1 GNRH1 GH1 CTNNB1 CDH1 BRAF
3
Show member pathways
12.84 PRL INS IGF1 GH1 CTNNB1 APC
4
Show member pathways
12.65 IGF1 CTNNB1 CDH1 BRAF APC
5
Show member pathways
12.63 INS IGF1 CTNNB1 CDH1 BRAF APC
6 12.57 PTCH1 IGF1 CTNNB1 CDH1 BRAF APC
7
Show member pathways
12.53 POU1F1 KRT14 IGF1 GHRL GH1
8
Show member pathways
12.44 NF1 INS IGF1 CTNNB1 CDH1 BRAF
9
Show member pathways
12.2 PTCH1 IGF1 CTNNB1 APC
10 12.17 PTCH1 IGF1 CTNNB1 BRAF
11 12.01 CTNNB1 CDH1 BRAF APC
12
Show member pathways
12 IGF1 GNRH1 GH1 CTNNB1 CDH1 BRAF
13 11.97 NF1 CTNNB1 CDH1 BRAF
14
Show member pathways
11.91 INS IGF1 GHRL GH1 CTNNB1
15 11.85 INS IGF1 GH1 CTNNB1
16 11.76 KRT14 CTNNB1 BRAF
17 11.69 PRL POU1F1 KRT14
18 11.67 CTNNB1 CDH1 APC
19 11.56 PTCH1 IGF1 GH1
20 11.4 NF1 IGF1 CTNNB1 BRAF APC
21 11.39 PRL LEPR INS
22 11.28 INS CTNNB1 CDH1
23 10.73 CTNNB1 CDH1
24 10.23 PRL LEPR INS GHRL

GO Terms for Craniopharyngioma

Cellular components related to Craniopharyngioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 TRH PRL LEPR INS IGF1 GNRH1
2 cell periphery GO:0071944 9.5 KRT8 KRT14 CTNNB1
3 beta-catenin destruction complex GO:0030877 9.43 CTNNB1 APC
4 Wnt signalosome GO:1990909 9.37 CTNNB1 APC
5 lateral plasma membrane GO:0016328 9.33 CTNNB1 CDH1 APC
6 flotillin complex GO:0016600 9.26 CTNNB1 CDH1
7 catenin complex GO:0016342 9.13 CTNNB1 CDH1 APC
8 endosome lumen GO:0031904 8.8 PRL INS GH1

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10 PRL POU1F1 INS IGF1 CTNNB1
2 regulation of gene expression GO:0010468 9.91 NF1 IGF1 GNRH1 CTNNB1 CDH1
3 negative regulation of apoptotic process GO:0043066 9.8 PROP1 IGF1 GNRH1 GHRL CTNNB1 BRAF
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 INS IGF1 GH1
5 response to nutrient levels GO:0031667 9.73 PRL GHRL GH1
6 dorsal/ventral pattern formation GO:0009953 9.67 PTCH1 PROP1 CTNNB1
7 negative regulation of angiogenesis GO:0016525 9.67 PRL NF1 GHRL CTNNB1
8 signal transduction GO:0007165 9.65 TRH PTCH1 PRL NF1 INS IGF1
9 negative regulation of endothelial cell proliferation GO:0001937 9.63 PRL NF1 GHRL
10 negative regulation of cell proliferation GO:0008285 9.63 PTCH1 POU1F1 NF1 GNRH1 CTNNB1 APC
11 positive regulation of multicellular organism growth GO:0040018 9.61 POU1F1 GHRL GH1
12 negative regulation of oligodendrocyte differentiation GO:0048715 9.6 NF1 CTNNB1
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.59 IGF1 GH1
14 positive regulation of growth GO:0045927 9.58 GHRL GH1
15 cell fate specification GO:0001708 9.58 POU1F1 CTNNB1 APC
16 adenohypophysis development GO:0021984 9.57 PROP1 POU1F1
17 entry of bacterium into host cell GO:0035635 9.55 CTNNB1 CDH1
18 positive regulation of glucose transmembrane transport GO:0010828 9.54 GH1 BRAF
19 cellular response to indole-3-methanol GO:0071681 9.52 CTNNB1 CDH1
20 somatotropin secreting cell differentiation GO:0060126 9.48 PROP1 POU1F1
21 pituitary gland development GO:0021983 9.43 PROP1 POU1F1 CDH1
22 regulation of cell proliferation GO:0042127 9.02 PTCH1 NF1 GHRL CTNNB1 BRAF

Molecular functions related to Craniopharyngioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gamma-catenin binding GO:0045295 9.26 CDH1 APC
2 beta-catenin binding GO:0008013 9.26 PROP1 CTNNB1 CDH1 APC
3 hormone activity GO:0005179 9.17 TRH PRL INS IGF1 GNRH1 GHRL
4 prolactin receptor binding GO:0005148 9.16 PRL GH1

Sources for Craniopharyngioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....